Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.
Miller VA, Kris MG, Shah N, Patel J, Azzoli C, Gomez J, Krug LM, Pao W, Rizvi N, Pizzo B, Tyson L, Venkatraman E, Ben-Porat L, Memoli N, Zakowski M, Rusch V, Heelan RT.
Miller VA, et al. Among authors: krug lm.
J Clin Oncol. 2004 Mar 15;22(6):1103-9. doi: 10.1200/JCO.2004.08.158.
J Clin Oncol. 2004.
PMID: 15020612